Quick Take
Axcella Health (AXLA) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing therapeutics for the treatment of metabolism-related conditions of the liver, muscles, and blood.
AXLA is not currently in clinical trials and is approaching most of its pipeline within the context of a medical food development program, rather than as FDA approved drugs.
Company & Technology
Cambridge, Massachusetts-based Axcella was founded in 2008 to develop new disease-specific endogenous amino acid profiles which safely reprogram metabolic